Work

A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Year: 2019

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz249.010

Authors: E. Jonasch, E.R. Plimack, T. Bauer, J.R. Merchan, K.P. Papadopoulos, D.F. McDermott, M.D. Michaelson, L.J. Appleman, S. Thamake, N. Zojwalla, T.K. Choueiri

Institutions: The University of Texas MD Anderson Cancer Center, Fox Chase Cancer Center, Sarah Cannon, University of Miami, South Texas Accelerated Research Therapeutics, Beth Israel Deaconess Medical Center, Harvard University, Massachusetts General Hospital, UPMC Hillman Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977883209

FWCI: 1.317

Cites:

Cited by: 14

Related to: 10